BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 25204450)

  • 21. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glioma grading capability: comparisons among parameters from dynamic contrast-enhanced MRI and ADC value on DWI.
    Choi HS; Kim AH; Ahn SS; Shin NY; Kim J; Lee SK
    Korean J Radiol; 2013; 14(3):487-92. PubMed ID: 23690718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assesment of perfusion in glial tumors with arterial spin labeling; comparison with dynamic susceptibility contrast method.
    Cebeci H; Aydin O; Ozturk-Isik E; Gumus C; Inecikli F; Bekar A; Kocaeli H; Hakyemez B
    Eur J Radiol; 2014 Oct; 83(10):1914-9. PubMed ID: 25087109
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiation of grade II and III oligodendrogliomas from grade II and III astrocytomas: a histogram analysis of perfusion parameters derived from dynamic contrast-enhanced (DCE) and dynamic susceptibility contrast (DSC) MRI.
    Lee JY; Ahn KJ; Lee YS; Jang JH; Jung SL; Kim BS
    Acta Radiol; 2018 Jun; 59(6):723-731. PubMed ID: 28862024
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic value of blood flow estimated by arterial spin labeling and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas.
    Rau MK; Braun C; Skardelly M; Schittenhelm J; Paulsen F; Bender B; Ernemann U; Bisdas S
    J Neurooncol; 2014 Dec; 120(3):557-66. PubMed ID: 25154323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.
    Anzalone N; Castellano A; Cadioli M; Conte GM; Cuccarini V; Bizzi A; Grimaldi M; Costa A; Grillea G; Vitali P; Aquino D; Terreni MR; Torri V; Erickson BJ; Caulo M
    Radiology; 2018 Jun; 287(3):933-943. PubMed ID: 29361245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.
    Law M; Yang S; Babb JS; Knopp EA; Golfinos JG; Zagzag D; Johnson G
    AJNR Am J Neuroradiol; 2004 May; 25(5):746-55. PubMed ID: 15140713
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of artery input function on dynamic contrast-enhanced MRI for determining grades of gliomas.
    Jia L; Wu X; Wan Q; Wan L; Jia W; Zhang N
    Br J Radiol; 2021 Mar; 94(1119):20200699. PubMed ID: 33332981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioma grading by dynamic susceptibility contrast perfusion and
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Reischl G; Bender B; Ernemann U; la Fougère C; Klose U
    Neuroradiology; 2018 Apr; 60(4):381-389. PubMed ID: 29464269
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DCE and DSC MR perfusion imaging in the differentiation of recurrent tumour from treatment-related changes in patients with glioma.
    Shin KE; Ahn KJ; Choi HS; Jung SL; Kim BS; Jeon SS; Hong YG
    Clin Radiol; 2014 Jun; 69(6):e264-72. PubMed ID: 24594379
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravoxel incoherent motion diffusion-weighted imaging analysis of diffusion and microperfusion in grading gliomas and comparison with arterial spin labeling for evaluation of tumor perfusion.
    Shen N; Zhao L; Jiang J; Jiang R; Su C; Zhang S; Tang X; Zhu W
    J Magn Reson Imaging; 2016 Sep; 44(3):620-32. PubMed ID: 26880230
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measurements of diagnostic examination performance and correlation analysis using microvascular leakage, cerebral blood volume, and blood flow derived from 3T dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in glial tumor grading.
    Server A; Graff BA; Orheim TE; Schellhorn T; Josefsen R; Gadmar ØB; Nakstad PH
    Neuroradiology; 2011 Jun; 53(6):435-47. PubMed ID: 20857284
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Whole-tumor histogram analysis of the cerebral blood volume map: tumor volume defined by 11C-methionine positron emission tomography image improves the diagnostic accuracy of cerebral glioma grading.
    Wu R; Watanabe Y; Arisawa A; Takahashi H; Tanaka H; Fujimoto Y; Watabe T; Isohashi K; Hatazawa J; Tomiyama N
    Jpn J Radiol; 2017 Oct; 35(10):613-621. PubMed ID: 28879406
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biopsy targeting gliomas: do functional imaging techniques identify similar target areas?
    Weber MA; Henze M; Tüttenberg J; Stieltjes B; Meissner M; Zimmer F; Burkholder I; Kroll A; Combs SE; Vogt-Schaden M; Giesel FL; Zoubaa S; Haberkorn U; Kauczor HU; Essig M
    Invest Radiol; 2010 Dec; 45(12):755-68. PubMed ID: 20829706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Whole-tumor histogram analysis of diffusion and perfusion metrics for noninvasive pediatric glioma grading.
    Su Y; Kang J; Lin X; She D; Guo W; Xing Z; Yang X; Cao D
    Neuroradiology; 2023 Jun; 65(6):1063-1071. PubMed ID: 37010573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Application of histogram analysis for the evaluation of vascular permeability in glioma by the K2 parameter obtained with the dynamic susceptibility contrast method: Comparisons with Ktrans obtained with the dynamic contrast enhance method and cerebral blood volume.
    Taoka T; Kawai H; Nakane T; Hori S; Ochi T; Miyasaka T; Sakamoto M; Kichikawa K; Naganawa S
    Magn Reson Imaging; 2016 Sep; 34(7):896-901. PubMed ID: 27109485
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volume-based histogram analysis of dynamic contrast-enhanced MRI for estimation of gliomas IDH1 mutation status.
    Hu Y; Zhang N; Yu MH; Zhou XJ; Ge M; Shen DD; Hua Y; Shi JL; Jia ZZ
    Eur J Radiol; 2020 Oct; 131():109247. PubMed ID: 32891974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
    Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
    Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Facing contrast-enhancing gliomas: perfusion MRI in grade III and grade IV gliomas according to tumor area.
    Di Stefano AL; Bergsland N; Berzero G; Farina L; Rognone E; Gastaldi M; Aquino D; Frati A; Tomasello F; Ceroni M; Marchioni E; Bastianello S
    Biomed Res Int; 2014; 2014():154350. PubMed ID: 24800207
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Improved T(1)-weighted dynamic contrast-enhanced MRI to probe microvascularity and heterogeneity of human glioma.
    Pauliah M; Saxena V; Haris M; Husain N; Rathore RK; Gupta RK
    Magn Reson Imaging; 2007 Nov; 25(9):1292-9. PubMed ID: 17490844
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.